{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:17:49Z","timestamp":1792199869648,"version":"4.4.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Systemic Lupus Erythematosus (SLE) mainly occurs during childbearing age. Remission or low disease activity state (LDAS) before conception are recommended by experts to achieve a favourable lupus pregnancy outcome but little is known on the best way to evaluate remission or activity status during pregnancy.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> We tested SLE-disease activity score (SLE-DAS) in the first trimester as predictor of maternal flares and obstetrical complications in 2nd and 3rd trimester in a cohort of SLE pregnant women.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> Inclusion criteria were: 1) women \u2265 18\u00a0years; 2) affected with SLE (SLICC 2012); 3) enrolled in two referral centers (Italy and France) 4) with an ongoing singleton pregnancy at 12\u00a0weeks (only one pregnancy per patient). Disease activity was assessed at first trimester of pregnancy, using SLE-pregnancy disease activity index (SLEPDAI) and retrospectively applying SLE-DAS. Maternal lupus flares at 2nd and 3rd trimester were defined by the SELENA-SLEDAI Flare Index (SFI). Adverse pregnancy outcome (APO) included: fetal and neonatal death, placental insufficiency with premature delivery &amp;lt;37\u00a0weeks, and small for gestational age (SGA) (\u22643rd percentile).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We included 158 pregnant patients affected with SLE. At first trimester the median SLEPDAI (IQR) was 2 (0\u20134) and the median SLE-DAS (IQR) 1.32 (0.37\u20132.08). At least one flare occurred in 25 (15.8%) women during the 2nd and 3rd trimester. APO occurred in 19 (12.0%) patients. A significant correlation between SLE-DAS and SLEPDAI was found in this cohort (Spearman\u2019s <jats:italic>\u03c1<\/jats:italic> = 0.97, <jats:xref>Figure 1<\/jats:xref>). At multivariate analysis, both SLE-DAS and SLEPDAI predicted maternal flares (adjOR = 1.2; 95% CI = 1.0\u20131.3, <jats:italic>p<\/jats:italic> = 0.02; adjOR 1.3, 95% CI = 1.1\u20131.6 per unit increase, <jats:italic>p<\/jats:italic> = 0.01, respectively). SLE-DAS and SLEPDAI were associated with APO at univariate analysis (<jats:italic>p<\/jats:italic> = 0.02).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> SLE-DAS was highly correlated with SLEPDAI and its use in the first trimester predicted maternal flares in the 2nd and 3rd trimester, making SLE-DAS a reliable instrument to measure SLE activity during pregnancy.<\/jats:p>","DOI":"10.3389\/fphar.2021.660123","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T19:09:45Z","timestamp":1618600185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy"],"prefix":"10.3389","volume":"12","author":[{"given":"Maddalena","family":"Larosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Guettrot-Imbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Le Guern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"In\u00eas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.autrev.2018.08.008","article-title":"Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies","volume":"18","author":"Andreoli","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/m14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1191\/096120399680411272","article-title":"Assessing disease activity in SLE patients during pregnancy","volume":"8","author":"Buyon","year":"1999","journal-title":"Lupus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/art.20864","article-title":"The impact of increased lupus activity on obstetric outcomes","volume":"52","author":"Clowse","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.berh.2017.09.011","article-title":"Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome","volume":"31","author":"Fischer-Betz","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0961203319836717","article-title":"Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients","volume":"28","author":"Jesus","year":"","journal-title":"Lupus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/1744666x.2019.1601557","article-title":"Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus","volume":"15","author":"Larosa","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000047157","article-title":"Definition of fetal growth restriction according to constitutional growth potential","volume":"80","author":"Mamelle","year":"2001","journal-title":"Neonatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/nejmoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/acr.23109","article-title":"Defining low disease activity in systemic lupus erythematosus","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/1744666x.2017.1327352","article-title":"Epidemiology of systemic lupus erythematosus","volume":"13","author":"Pons-Estel","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1136\/annrheumdis-2017-211814","article-title":"Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)","volume":"76","author":"Ugarte-Gil","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann. Rheum. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.660123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T19:09:49Z","timestamp":1618600189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.660123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":22,"alternative-id":["10.3389\/fphar.2021.660123"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.660123","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"article-number":"660123"}}